CSTONE PHARMA-B: ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2023
Apr 23 05:01 ET
CSTONE PHARMA-B: PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION
Apr 15 05:02 ET
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE ACCEPTANCE OF RET INHIBITOR GAVRETO (PRALSETINIB) MANUFACTURING LOCALIZATION APPLICATION BY CENTER FOR DRUG EVALUATION OF CHINA NMPA
Apr 8 20:00 ET
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
Apr 5 04:30 ET
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES THE FIFTH INDICATION APPROVED FOR SUGEMALIMAB IN CHINA AS FIRST-LINE TREATMENT OF GASTRIC CANCER
Mar 15 00:00 ET
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024
Mar 6 03:30 ET
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT
Mar 3 23:27 ET
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024
Feb 6 06:01 ET
CSTONE PHARMA-B: LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS
Jan 23 04:06 ET
CSTONE PHARMA-B: LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS
Jan 23 04:00 ET
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023
Jan 5 05:41 ET
CSTONE PHARMA-B: FORM OF PROXY FOR EXTRAORDINARY GENERAL MEETING
Dec 28, 2023 04:09 ET
CSTONE PHARMA-B: INSIDE INFORMATION ANNOUNCEMENT - LATEST BUSINESS UPDATE
Dec 20, 2023 03:30 ET
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES INCLUSION OF AYVAKIT (AVAPRITINIB) IN 2023 CHINA''S NATIONAL REIMBURSEMENT DRUG LIST
Dec 12, 2023 23:09 ET
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES NMPA APPROVAL OF SUGEMALIMAB AS FIRST-LINE TREATMENT FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA
Dec 7, 2023 23:00 ET
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2023
Dec 6, 2023 03:30 ET
CSTONE PHARMA-B: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2023
Nov 6, 2023 03:45 ET
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES STRATEGIC PARTNERSHIP AND EXCLUSIVE LICENSING AGREEMENT WITH 3SBIO FOR NOFAZINLIMAB (ANTI-PD-1 ANTIBODY) IN MAINLAND CHINA
Nov 1, 2023 06:00 ET
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES NMPA APPROVAL OF SUGEMALIMAB FOR PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA, THE FIRST ANTI-PD-1/PD-L1 MAB APPROVED FOR THIS INDICATION
Oct 30, 2023 20:00 ET
CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CSTONE SHOWCASED, IN AN ORAL SESSION, LATE-BREAKING RESULTS FROM PHASE 3 STUDY OF SUGEMALIMAB IN FIRST-LINE GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AT ESMO 2023
Oct 24, 2023 00:00 ET
No Data
No Data